Alzheimer disease (AD) is characterized by the accumulation of amyloid plaques, which are predominantly composed of amyloid-b peptide 1 . Two principal physiological pathways either prevent or promote amyloid-b generation from its precursor, b-amyloid precursor protein (APP), in a competitive manner 1 . Although APP processing has been studied in great detail, unknown proteolytic events seem to hinder stoichiometric analyses of APP metabolism in vivo 2 . Here we describe a new physiological APP processing pathway, which generates proteolytic fragments capable of inhibiting neuronal activity within the hippocampus. We identify higher molecular mass carboxy-terminal fragments (CTFs) of APP, termed CTF-g, in addition to the long-known CTF-a and CTF-b fragments generated by the a-and b-secretases ADAM10 (a disintegrin and metalloproteinase 10) and BACE1 (b-site APP cleaving enzyme 1), respectively. CTF-g generation is mediated in part by membrane-bound matrix metalloproteinases such as MT5-MMP, referred to as g-secretase activity. g-Secretase cleavage occurs primarily at amino acids 504-505 of APP 695 , releasing a truncated ectodomain. After shedding of this ectodomain, CTF-g is further processed by ADAM10 and BACE1 to release long and short Ag peptides (termed Ag-a and Ag-b). CTFs produced by g-secretase are enriched in dystrophic neurites in an AD mouse model and in human AD brains. Genetic and pharmacological inhibition of BACE1 activity results in robust accumulation of CTF-g and Ag-a. In mice treated with a potent BACE1 inhibitor, hippocampal long-term potentiation was reduced. Notably, when recombinant or synthetic Ag-a was applied on hippocampal slices ex vivo, longterm potentiation was lowered. Furthermore, in vivo single-cell two-photon calcium imaging showed that hippocampal neuronal activity was attenuated by Ag-a. These findings not only demonstrate a major functionally relevant APP processing pathway, but may also indicate potential translational relevance for therapeutic strategies targeting APP processing. To identify new proteolytic pathways of APP, we searched for CTFs other than those giving rise to P3 fragment (CTF-a) or amyloid-b (CTF-b) [3][4][5] . A new CTF with an approximate molecular mass of 30 kilodaltons (kDa) was revealed, which was recognized by an antibody to the C terminus of APP (Y188) and was absent in the brains of APPknockout mice 6 (Fig. 1a and Supplementary Table 1 ). The molecular mass of the novel CTF suggests an additional physiological cleavage of APP amino-terminal to the known cleavage sites of b-and a-secretases, which we named accordingly g-cleavage of APP (Extended Data   Fig. 1 ). In the soluble fraction, we detected the N-terminal cleavage product (sAPP-g; Extended Data Fig. 2) , with a molecular mass of approximately 80 kDa that distinguishes it from alternative N-terminal APP fragments described previously [7][8][9] . In addition, we observed lower molecular mass soluble peptides (Ag), which presumably derived from processing of CTF-g by BACE1 (Ag-b) or ADAM10 (Ag-a), or alternatively from sAPP-a/b cleavage (Fig. 1b) . Ag was identified in the soluble fraction of mouse brains as several closely spaced peptides by antibody M3.2 (Fig. 1b) , demonstrating that some of these fragments contain the N-terminal part of the amyloid-b domain and probably end at the a-secretase cleavage site. Ag fragments were further validated by antibody 9478D directed against an epitope N-terminal to the amyloid-b domain (Fig. 1b) . Consistent with g-secretase cleavage of APP in wild-type mice, we observed increased CTF-g and Ag production in brain homogenates of APPPS1-21 transgenic mice 10 (Fig. 1c, d ). Furthermore, antibody 192swe selectively identified the Ag-b species ending at the BACE1 cleavage site (Fig. 1d) . Consistent with increased BACE1 cleavage of Swedish mutant APP, only minor amounts of Ag-a were detected in this mouse model with antibody 2D8 (Fig. 1d) . Physiological g-secretase processing was further confirmed in cerebrospinal fluid (CSF) from humans with and without the Swedish mutation (APP swe ) (Fig. 1e) . Fivefold higher Ag than amyloid-b levels were observed in human CSF (5.33 6 1.39 times (mean 6 s.d.) higher Ag than amyloid-b estimated by 2D8 blot signals; n 5 7, P . 0.0001, Student's t-test). Using antibody 192swe, Ag-b was selectively detected in the CSF of patients with the Swedish mutation, whereas antibodies 2E9 and 2D8 detected Ag-a in all analysed samples (Fig. 1e) . Moreover, while these peptides are generated by g-secretase cleavage N-terminal to the amyloid-b domain, they do not reach the c-secretase site (see mass spectrometric analysis in Fig. 1f ), demonstrating that they are different to the previously described N-terminally extended amyloidb variants 11,12 . Membrane-bound matrix metalloproteinases such as MT1-MMP and MT5-MMP (also known as MMP14 and MMP24, respectively) were shown to cleave APP in vitro at a site consistent with the molecular mass of g-secretase processing products 13,14 . We therefore produced a neo-epitope-specific antibody (10A8; Extended Data Fig. 2 ) to identify the g-secretase cleavage site. Antibody 10A8 detected a protein corresponding to sAPP-g with an approximate molecular mass of 80 kDa in mouse brain lysates, which was absent in the APP-knockout mouse brain (Extended Data Fig. 2) . Thus, g-secretase cleavage of APP may occur in vivo at least in part at amino
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While investigating protease inhibitors capable of blocking g-secretase, we observed that pharmacological BACE1 inhibition led to a pronounced accumulation of the long Ag-a species in Chinese hamster ovary (CHO) 7PA2 cells (Fig. 2a) . This indicates that after blockade of b-secretase activity, processing by a-secretase leads to enhanced production of the long Ag-a species at the expense of the shorter BACE1-generated Ag-b. Similarly, BACE1 inhibition also led to an accumulation of endogenous CTF-g and enhanced production of endogenous Ag-a in primary mouse hippocampal neurons (Fig. 2b, c) , as well as human neurons differentiated from embryonic pluripotent stem cells (H9 cells 17 ; Fig. 2d-g ). Furthermore, in human neurons we not only detected a 65% increase (Fig. 2g) in the slightly longer Ag-a species after BACE inhibition, but also a concomitant decrease in Ag-b peptides (Fig. 2e, top) . Importantly, g-secretase processing significantly exceeded amyloidogenic processing (9.5 6 1.87 times Ag compared to amyloid-b estimated for human neurons; n 5 8, P . 0.001, Student's t-test). Pharmacological intervention with a BACE1 inhibitor in vivo caused a clear and timedependent increase in CTF-g and Ag-a levels in APP V717I transgenic mice 18 (Fig. 2h) , which was fully reversible within 24 h after administration. In agreement, increased CTF-g and Ag-a levels were also observed in a BACE1-knockout mouse 19 in vivo (Fig. 2i ). To identify a potential contribution of g-secretase processing to AD pathology, immunohistochemical analyses were performed with brains derived from six-month-old APPPS1-21 (ref. 20) mice (Extended Data Fig. 5a ). This revealed co-labelling of antibody Y188 with antibody 2E9 in dystrophic neurites. No signal for Ag peptides was obtained in plaque cores in which aggregated amyloid-b was detected by 6E10 staining (Extended Data Fig. 5a ). Similar data were obtained in human AD brains (Extended Data Fig. 6 ). To verify accumulation of CTF-g in dystrophic neurites, we used laser capture microdissection (LCM). Western blot analysis revealed not only CTF-b and CTF-a, but also CTF-g within the halo, but not within the plaque core area or regions devoid of plaques (Extended Data  Fig. 5b ). As expected, amyloid-b was observed within the plaque core as well as in the surrounding halo (Extended Data Fig. 5b ).
Since the cleavage products of g-secretase APP processing accumulate after BACE1 inhibition and are enriched in dystrophic neurites, we examined whether soluble Ag peptides interfere with neuronal function, similar to soluble amyloid-b oligomers 1 . Long-term potentiation (LTP) is considered as a synaptic correlate of memory, and is widely used as a model for investigating the neurotoxic effects of amyloid-b oligomers on synaptic function [21] [22] [23] . A single oral dose of the BACE1 inhibitor SCH1682496 increased the CTF-g levels, and almost doubled the Ag-a level in soluble brain extracts prepared from animals 3 h after treatment (Extended Data Fig. 7 ). This was accompanied by a significant reduction of hippocampal LTP (Fig. 3a, b) . These findings may suggest an involvement of Ag-a in LTP deficit under acute blockade of b-secretase activity. To validate the potential effects of Ag peptides on synaptic transmission and plasticity directly, we expressed Ag-b and Ag-a in CHO cells (Fig. 3c) . Concentrated conditioned media was further enriched for Ag by size-exclusion chromatography (SEC) and applied to hippocampal slices before LTP induction in CA1 pyramidal neurons. Neither Ag-b nor Ag-a influenced the baseline synaptic transmission (Extended Data Fig. 8 ).
Comparison of LTP 60 min after its induction in the presence of Ag-b or Ag-a with control conditions (Fig. 3d-g ) revealed that Ag-a lowered the LTP to a degree comparable to synthetic amyloid-b dimers 23 (Extended Data Fig. 9a, b) , while truncated Ag-b had no effect (Fig. 3e, g ). In support of this observation, synthetic Ag-a reduced LTP to a similar extent at a concentration of 100 nM (Extended Data Fig. 9c, d ). To examine the direct effects of Ag peptides on neuronal activity in vivo, we used two-photon calcium imaging at single-cell resolution 24, 25 . Figure 4a -d illustrates results from experiments in which the activity of neurons in the CA1 pyramidal cell layer was monitored before and after superfusion of the exposed hippocampus with Ag peptides or the respective control peptides. Ag-a strongly suppressed the activity of hippocampal neurons in vivo, an effect not observed with Ag-b or the control peptide (Fig. 4a-d and Extended Data Fig. 10 ). By using local application of synthetic Ag-a to hippocampal neurons, we demonstrate that the inhibitory effect of Ag-a on neurons was readily reversible after Mem. a, Conditioned media from 7PA2 cells treated with or without a BACE1 inhibitor (BI) was co-migrated with synthetic Ag-b and Ag-a peptides and immunoblotted with 2D8 and 2E9 antibodies. b-f, After BACE inhibition in mouse hippocampal neurons and human neurons, a reduction of sAPP-b was accompanied by a strong increase in endogenous Ag-a and CTF-g levels. Lys., lysate; sup., supernatant. g, Quantification of intensities for 2D8 signals in e (n 5 8; ***P , 0.001, Student's t-test). h, BACE1 inhibition in vivo resulted in enhanced production of Ag-a species in APP V717I mice. Background bands are indicated by asterisks. i, Western blot analysis of soluble extracts of P10 Bace1 2/2 mouse brains revealed a marked increase in Ag-a peptides as compared to controls. washout ( Fig. 4e) . A summary of the results from all experiments is shown in Fig. 4f , g. We have identified a new APP processing pathway that exceeds amyloidogenic processing. Similar to amyloid-b production 26 , the alternative proteolytic processing pathway occurs under physiological conditions but may be altered during AD pathogenesis. Accumulation of g-secretase 27 and CTF-g within dystrophic neurites in close vicinity to neuritic plaques may also support its potential contribution to AD pathology. However, all APP and presenilin-associated familial AD mutations affect amyloid-b production and aggregation (reviewed in ref. 26), whereas the Icelandic mutation APP A673T prevents AD and dementia by moderately reducing amyloid-b production 28 . Indeed, the Swedish mutation decreased Ag-a by strongly enhancing BACE1-mediated APP processing. However, g-secretase accumulation 27 and its activity near amyloid plaques may suggest that g-secretase stimulation by amyloid-b could be a downstream effector within the amyloid cascade. Although Ag may be involved in the modulation of neuronal activity and synaptic plasticity, the differential bioactivity of recombinant Ag-a and Ag-b is currently unclear. One may speculate that the longer Ag-a peptide is more stable owing to unknown post-translational modifications. This would be consistent with our observation that, in contrast to cell-produced Ag-b, 100 nM of synthetic Ag-b inhibits LTP (data not shown). Finally, it is important to note that low-n amyloid-b oligomer preparations from 7PA2 supernatants contain considerable amounts of Ag (data not shown). Thus, the previously observed inhibition of LTP with such fractions may also be attributed to the presence of Ag. Our findings may also be considered in the context of continuing clinical trials with BACE1 inhibitors. Together with the identification of numerous brain-specific BACE1 substrates 29, 30 , our data indicate that therapeutic inhibition of BACE1 activity requires careful titration to prevent unwanted adverse effects at several levels.
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Supplementary Information is available in the online version of the paper. were grown in DMEM/F12 (Thermo Scientific) supplemented with 10% FCS (Thermo Scientific) plus penicillin/streptomycin and non-essential amino acids (PAA) in a humid incubator with 5% CO 2 at a temperature of 37 uC. For inhibitor treatment, cell culture medium was replaced with fresh, pre-warmed serum free medium (OPTIMEM; Thermo Scientific) supplemented with inhibitors or DMSO as vehicle control. Treatment was initiated when cells reached 90-100% confluency and conditioned media were collected after 20-24 h. Supernatants were cleared by centrifugation (10 min, 5,500g at 4 uC). To obtain cell lysates, cell monolayers were washed once with ice-cold PBS and detached in 1 ml PBS using a cell scraper. The cell suspension was pelleted by centrifugation (5 min, 1,000g at 4 uC) and lysed with RIPA buffer (20 mM sodium citrate, pH 6.4, 1 mM EDTA, 1% Triton X-100 in ddH 2 O) supplemented with Protease Inhibitor Cocktail (SigmaAldrich). The protein concentration of lysates was determined using the Uptima BC Assay Protein Quantitation kit (Interchim). Primary cell culture. Hippocampal neurons were isolated from embryonic day 18 CD rats (Charles River) as described previously 32 . Dissociated neurons were plated at 17,700 cells cm 22 onto 6-cm dishes coated with poly-L-lysine (1 mg ml 21 ; Sigma) and cultured in Neurobasal medium supplemented with 2% B27 and 0.5 mM L-glutamine (all from Invitrogen). Hippocampal cultures were maintained in a humidified 5% CO 2 incubator at 37 uC. For inhibitor treatment, DIV16 culture medium was replaced with fresh, pre-equilibrated N2 medium (supplemented with 20% of 4 days conditioned N2 medium from pure primary cultured astrocytes) to which inhibitors or DMSO as vehicle control were added. Generation and BACE1 inhibition of cerebral cortex neurons induced from human embryonic stem cells. Cell lines in this study were H9 ES (WiCell Research Institute) 33 . Pluripotent cells were cultured on mouse embryonic fibroblasts (GlobalStem) in DMEM/F12 containing 20% (v/v) KSR, 100 mm non-essential amino acids, 100 mM 2-mercaptoethanol, 50 U ml 21 penicillin and 50 mg ml 21 streptomycin (Life Technologies) and 10 ng ml 21 FGF2. Directed differentiation of human embryonic stem cells to cerebral cortex neurons was carried out as described 17, 34 . Human neurons (75 days after induction) were treated with 1 mM b-secretase inhibitor LY2886721 (Selleck) dissolved in DMSO (20 mM stock). Vehicle-only control assays were performed using DMSO. The compound was applied twice at 48-h intervals. Extracellular media was collected before drug addition and at subsequent 48-h intervals. Neurons were collected after 4 days of treatment using 0.5 mM EDTA in PBS. Transgenic mice, animal care and animal handling. Bace1 2/2 and APPPS1-21 mice were described before 10,19 and were bred for this study in a Bl6C57/J background. All treatments were approved by the local committee for animal use and were performed in accordance to state and federal regulations (license number KVR-I/221-TA116/09). Mice had access to pre-filtered sterile water and standard mouse chow (Ssniff Ms-H, Ssniff Spezialdiäten GmbH, Soest, Germany) ad libitum and were housed under a reversed day-night rhythm in IVC System Type II L-cages (528 cm The BACE1 inhibitor was diluted in 5% ethanol (Merck) and 10% solutol (SigmaAldrich) in sterile water (Baxter). Animals were sacrificed after 5, 8 and 24 h. Mice were anaesthetized with 3.5 ml per gram body weight of a mixture of ketamine (115 mg ml 21 ketamine hydrochloride, Eurovet), xylazin 2% (23.32 mg ml 21 xylazine hydrochloride, VMD Arendonk), atropine (0.50 mg ml 21 atropine sulphate, Sterop) and saline (8:5:2:5, v/v/v/v). For brain preparation, mice were flushed trans-cardially with ice-cold saline (3.5 ml min
21
, 3 min). The brain was removed from the cranium and dissected into left and right hemiforebrain, brainstem, cerebellum and olfactory bulb. The brain structures were promptly immersed in liquid nitrogen and stored at 280 uC. Different tissues (kidneys, spleen, liver, stomach, gut, lungs and heart) were examined and checked for gross abnormalities. No obvious abnormalities were observed in any of the treatment groups. Preparation of protein extracts from brain. Brains were removed from the cranium and dissected into left and right hemispheres. Brain tissue was snapfrozen in liquid nitrogen and stored at 280 uC. Soluble proteins were extracted with DEA buffer (50 mM NaCl, 0,2% diethylamine, pH 10, plus protease inhibitor (P8340, Sigma-Aldrich)) 36 , membrane proteins were extracted with RIPA buffer (20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA,1% NP-40,1% sodium deoxycholate, 2.5 mM sodium pyrophosphate plus protease inhibitor) or applying a membrane preparation protocol as described before 37 . Protein analysis. Proteins were separated under denaturing conditions using discontinuous SDS-PAGE. Equal amounts of proteins denatured in Laemmli buffer were loaded onto the gel and 10 ml of the SeeBlue Plus2 Prestained Standard (Invitrogen) served as molecular mass marker. Electrophoresis was performed in Tris-glycine buffer (25 mM Tris, 190 mM glycine in ddH 2 O) using the Mini-PROTEAN system (BIORAD) on activated PVDF membranes. Low molecular mass proteins (,16 kDa) were separated using precast gradient Tricine Protein Gels (10-20%, 1 mm, Novex) in Tris-tricine buffer using the XCell SureLock Mini-Cell system (Novex). After separation by SDS-PAGE, proteins were transferred onto membranes using the tank/wet Mini Trans-Blot cell system (BIORAD). CTFs, Ag and amyloid-b were detected after transfer on Nitrocellulose membranes (Protran BA85; GE Healthcare), while other proteins were blotted on PVDF (Immobilon-P, Merck Millipore). As size markers for Ag synthetic peptides Ag-b (92 amino acids; 1-MISEPRISYGNDALMPSLTETKT TVELLPVNGEFSLDDLQPWHSFGADSVPANTENEVEPVDARPAADRGLTT RPGSGLTNIKTEEISEVKM-92) and the slightly longer Ag-a (108 amino acids; 1-MISEPRISYGNDALMPSLTETKTTVELLPVNGEFSLDDLQPWHSFGADSV PANTENEVEPVDARPAADRGLTTRPGSGLTNIKTEEISEVKMDAEFRHDSG YEVHHQK-108) were obtained from Peptide Speciality Laboratories. After completion of the transfer and before blocking, proteins transferred to nitrocellulose membranes were additionally denatured by boiling the membrane in PBS (140 mM NaCl, 10 mM Na 2 HPO 4 , 1.75 mM KH 2 PO 4 , 2.7 mM KCl in ddH2O, pH 7.4) for 5 min. After cooling to room temperature, nitrocellulose membranes as well as the PVDF membranes were blocked in I-Block solution (0.2% Tropix I-Block (Applied Biosystems), 0.1% Tween20 in PBS) for 1 h at room temperature or overnight at 4 uC (with agitation). Transferred proteins were detected using immunodetection and enhanced chemiluminescence (ECL). First, blocked membranes were incubated with primary antibodies diluted in I-Block solution overnight at 4 uC (with agitation). After removal of the antibody, membranes were washed three times in TBS-T buffer (10 min each, at room temperature, with agitation; 140 mM NaCl, 2.68 mM KCl, 24.76 mM Tris, 0.3% Triton X-100 in ddH 2 O, pH 7.6) and subsequently incubated with a horseradish-peroxidasecoupled secondary antibody (obtained from Promega or Santa Cruz). Secondary antibodies were diluted in I-Block solution and membranes were incubated for 1 h at room temperature (with agitation) followed by three washes in TBS-T. For ECL detection, membranes were incubated with horseradish peroxidase substrate (ECL, GE Healthcare or ECL Plus, Thermo Scientific) for 1 min at room temperature and signals were captured with X-ray films (Super RX Medical X-Ray, Fujifilm), which were subsequently developed using an automated film developer (CAWOMAT 2000 IR, CAWO). Quantitation of protein was conducted using ImageJ software. Ratios were obtained from signals on the same film for Ag over amyloid-b. Quantitative data were analysed statistically by using a two-tailed Student's t-test. Molecular cloning and transfection. For the expression of Ag-a and Ag-b in CHO cells, the complementary DNAs of the respective fragments were amplified by PCR and subcloned into the pSecTag2A (Invitrogen) vector that features an N-terminal secretion signal. CHO cells were cultured in DMEM with 10% FCS and non-essential amino acids. Transfections were carried out using Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions. Mass spectrometry analysis of samples. Beads with immunoprecipitated peptides were resuspended in ddH 2 O and reduced with 10 mM dithiothreitol followed by alkylation with 55 mM 2-chloroacetamide. Samples were divided into three parts and digested with either 1 mg of trypsin (1.2 M urea, 0.4 M thiourea and 50 mM ammonium bicarbonate), LysC (5 M urea, 1.7 M thiourea and 50 mM ammonium bicarbonate) or chymotrypsin (0.3 M urea, 0.1 M thiourea and 50 mM ammonium bicarbonate). To increase the sequence coverage further, partially cleaved peptides were generated by digesting for 5, 10, 20, 40, 60, 120, 180 and 720 min. Samples from all time points of a respective protease were pooled and desalted on stage tips 38 . For liquid chromatography-tandem mass spectrometry (LC-MS/MS), peptides were separated on a Thermo Scientific EASY-nLC 1000 HPLC system (Thermo Fisher Scientific) and in-house packed columns (75 mm inner diameter, 20 cm length, 1.9 mm C18 particles (Dr. Maisch GmbH). The peptide mixture was loaded in buffer A (0.5% formic acid) and separated with a gradient from 10% to 60% buffer B (80% acetonitrile, 0.5% formic acid) within 40 min at 250 nl min 21 at a column temperature of 50 uC. A Quadrupole Orbitrap mass spectrometer 39 (Q Exactive, Thermo Fisher Scientific) was coupled to the HPLC system via a nano electrospray source. We used data-dependent acquisition with a survey scan range of 300 to 1,650 m/z, at a resolution of 60,000 m/z and selected up to five most abundant features with a charge state $2 for HCD fragmentation 40 at a normalized collision energy of 27 and a resolution of 15,000 at m/z 200. To limit repeated
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sequencing, dynamic exclusion of sequenced peptides was set to 20 s. Thresholds for ion injection time and ion target values were set to 20 ms and 3 3 10 6 for the survey scans, and 120 ms and 1 3 10 5 for the MS/MS scans. Data were acquired using the Xcalibur software (Thermo Scientific). Data analysis. To process mass spectrometry raw files, we used the MaxQuant software (v1.5.2.16) 41 . We used the Andromeda search engine 42 , which is integrated into MaxQuant, to search MS/MS spectra against the APP 695 and 247 common contaminating proteins 42 . We set enzyme specificity to unspecific to detect novel cleavage sites and set a peptide search length from 7 to 40 amino acids. A false discovery rate cutoff of 1% was applied at the peptide level. For data visualization we used R 43 . Identified peptides were mapped to APP 695 . To display quantitative evidence for overlapping peptides, intensities of identified peptides were summed and plotted per amino acid residue. The data of the individual immunoprecipitation and mass spectrometry analyses are depicted in Extended Data Fig. 3 . Human CSF samples. Human CSF samples collected at the Department of Neurology Outpatient unit for neurodegenerative disease (KBFZ) of the University of Bonn were obtained by lumbar puncture at position L3, centrifuged and divided in small aliquots. For further analysis, samples were stored at 280 uC. Turbid or blood-contaminated samples were excluded from analysis. Use of these samples for research purposes has been consented by all patients according to the ethical committee requirements of the University of Bonn Ethical committee and approval number 279/10. For the analysis of APP swe carriers with antibodies 192swe (ref. 44 ) lumbar CSF was obtained from family members. Tubes with CSF were stored at 270 uC until analysis. The clinical diagnosis of probable AD was based on NINCDS-ADRDA criteria 45 . The diagnosis of AD was confirmed by neuropathological examination of the brain of one deceased mutation-carrier 46, 47 . This study was approved by research ethics committee at the Uppsala University Hospital (Dnr 048-2005). Neuropathology and immunohistochemistry. Use of brain samples for research purposes has been consented by all patients according to the ethical committee requirements of the University of Ulm Ethical committee and approval number 54/08. Braak-NFT stages 48 , and CERAD 49 scores for neuritic plaques were used to determine the degree of AD pathology according to the NIA-AA guidelines 50 . Consecutive paraffin sections from the human medial lobe were stained with 22C11, 9476M and 9478D. Primary antibodies were detected with biotinylated anti-mouse and anti-rabbit IgG secondary antibodies and visualized with avidinbiotin-complex (ABC-Kit, Vector Laboratories) and diaminobenzidine-HCl (DAB). The sections were counterstained with haematoxylin. Positive and negative controls were performed. 9476M and 9478D stainings were assessed in 10 control and 10 AD patient cases.
For double immunofluorescence analysis of APPPS1-21 brain sections, 6-month-old mice were killed by CO 2 inhalation according to animal handling laws. Brains were dissected and fixed with 4% paraformaldehyde in 0.1 M PBS, pH 7.4 for 48 h. For immunohistochemistry, 25-mm-thick sagittal mouse brain cryosections were treated with 10 mM sodium citrate, pH 6 at 95 uC for 20 min, washed with 0.5% Triton X-100 in PBS, blocked with 5% goat serum (Invitrogen) and 0.5% Triton X-100 in PBS for 1 h and subsequently incubated overnight with primary antibodies diluted in blocking solution. Primary antibodies were used as listed in Supplementary Table 1 . DAPI was used to counterstain nuclei. Signals were visualized using fluorescently labelled secondary antibodies. Confocal images were acquired using a Plan-Apochromat 253/0.8 oil differential interference contrast objective on a LSM 710 confocal microscope (Zeiss) in sequential scanning mode using ZEN 2011 software package (black edition, Zeiss). LCM of plaque enriched brain material. For laser capture microdissection of plaque cores and halos, 10-, 11-, 14-, 16-and 24-month-old transgenic APPPS1-21 mice were used according to a previously published protocol 51 with slight modifications. Mice brains were dissected and immediately frozen on crushed dry ice. Ten-micrometre-thick sagittal sections were cut using a Microm HM 560 cryostat (Thermo Scientific), mounted on frame slides containing a 1.4 mm polyethylene terephthalate membrane (Leica Microsystems) and subsequently stained or stored at 280 uC for later usage. Staining was performed as follows: brain sections were thawed briefly at room temperature, fixed with 75% ethanol for 1 min, stained with 0.05% Thioflavin-S for 5 min, washed with 75% ethanol and dried at room temperature. LCM was performed on the same day using a laser dissection microscope (Leica, LMD 7000) with the following settings: excitation wavelength 495 nm, laser power 30, aperture 5, speed 6 and pulse frequency 119. From each animal, at least 800 plaque cores and halos, dissected from 12 brain sections were cut using a 633 magnification objective, collected in 0.5 ml caps (Leica Microsystem) and subsequently pooled for protein analysis. Areas containing no plaques were cut using a 103 magnification objective and were used as controls. Protein lysates were done essentially as described above using RIPA with 0.1% SDS.
Slice preparation and electrophysiological recordings applying Ag peptides in vitro. Transverse hippocampal slices (350 mm) were prepared from P20-30 Swiss mice following standard procedures 52 . Slices were cut in ice-cold oxygenated (95% O 2 , 5% CO 2 ) solution containing 206 mM sucrose, 2.8 mM KCl, 1.25 mM NaH 2 PO 4 , 2 mM MgSO 4 , 1 mM MgCl 2 , 1 mM CaCl 2 , 26 mM NaHCO 3 , 0.4 mM sodium ascorbate and 10 mM glucose, pH 7.4. For recovery (1 h), slices were incubated at 27 uC in oxygenated standard ACSF containing: 124 mM NaCl, 2.8 mM KCl, 1.25 mM NaH 2 PO 4 , 2 mM MgSO 4 , 3.6 mM CaCl 2 , 26 mM NaHCO 3 , 0.4 mM sodium ascorbate, 10 mM glucose (pH 7.4) 53 . Slices were inspected in a chamber on an upright microscope (Slicescope, Scientifica Ltd) with infrared differential interference contrast illumination, and were perfused with the oxygenated ACSF at 27 6 1 uC. fEPSPs were recorded in the stratum radiatum of the CA1 region using a glass electrode (filled with 1 M NaCl, 10 mM HEPES, pH 7.4) and the stimuli (30% of maximal fEPSP) were delivered to the Schaeffer Collateral pathway by a monopolar glass electrode (filled with ACSF). Electrodes were specifically placed just below the surface of the slice to maximize the exposure to circulating peptides. A minimum of 15-20 min stable baseline was first obtained in standard ACSF followed by another 15-20 min of bath application of ACSF containing SEC fractions (CHO, Ag-a or Ag-b; 1/15 dilution, interleaved recordings) using re-circulation with a peristaltic pump at 2.5-3 ml min 21 while being continuously aerated with 95% oxygen. No alterations in fEPSP baseline responses were observed after incubation with the SEC fractions (Extended Data Fig. 8 ). In the continuous presence of ACSF/SEC solution, LTP was induced using a high-frequency stimulation protocol with two pulses of 100 Hz for 1 s with a 20 s interval between pulses, and recorded for 1 h. Control recordings (no application of SEC fractions) were obtained in an interleaved fashion in which ACSF was re-circulated using an identical procedure. For LTP analysis, the first third of the fEPSP slope was calculated in baseline condition (15-20 min before induction of LTP) and compared to that after LTP induction (60 min after tetanization of Schaffer collaterals). The average baseline value was normalized to 100% and all values of the experiment were normalized to this baseline average (1-min bins). Experimental data were pooled per condition and presented as mean 6 s.e.m. Data analysis was performed with the Clampfit software (Molecular Devices). The test samples were blinded to the investigator and uncoded at the end of the experiments. Statistical analysis was performed using GraphPad (Prism 6) with the last 15 min of the recordings compared to measurements of 15-20 min of baseline, using a two-tailed Student's t-test for statistical analysis on two samples or one-way ANOVA and post hoc Bonferroni test for statistical analysis on three and more samples, with P , 0.05 taken as statistically significant. No power analysis was done to estimate sample size, and there was no randomization. Electrophysiological recordings of the effects of BACE1 inhibitor in vitro. BACE1 inhibitor (100 mg kg 21 , single gavage) or vehicle-treated mice (12 weeks old) were deeply anaesthetized with isoflurane (1% in O 2 ) and decapitated with brains rapidly extracted and placed for 5-6 min in ice-cold bubbled (95% O 2 , 5% CO 2 ) slicing solution (in mM): 75 sucrose, 85 NaCl, 2.5 KCl, 1.25 NaH 2 PO 4 , 25 NaHCO 3 , 0.5 CaCl 2 , 4 MgCl 2 , 25 glucose, pH 7.4. Coronal slices (400 mm) containing the hippocampus were cut (VT1200S; Leica) and transferred into a warming chamber (35 uC) filled with bubbled solution of the same composition, except sucrose was omitted and NaCl increased to 125 mM (30 min). This was followed by the transfer of slices into recording ACSF (in mM): 125 NaCl, 2.5 KCl, 1.25 NaH 2 PO 4 , 25 NaHCO 3 , 2 CaCl 2 , 2 MgCl 2 , 25 glucose. Recordings of fEPSP were made from the hippocampal CA1 area. A glass bipolar stimulating electrode was placed in the stratum radiatum of CA2-CA3 subfields to stimulate Schaffer collaterals with 0.2 ms current pulses at 0.033 Hz (A-360, WPI), with evoked responses recorded in the stratum radiatum of CA1 area. Incrementing current pulses (0.2 mA) were used for obtaining stimulus-response relationship graphs. Stable baseline and LTP recordings were made using one-half of the maximal stimulus intensities; LTP was induced by high-frequency stimulation of Schaffer collaterals with 10 trains of 10 pulses at 100 Hz applied, with 2-s inter-train intervals. Signals were filtered at 5 kHz, digitally sampled at 10 kHz and stored for offline analysis. The relative slope and peak amplitude of evoked fEPSPs were measured using FitMaster (HEKA Electronics). The groups of treated mice were blinded to the investigator and uncoded at the end of the experiments. A one-way ANOVA and post hoc Bonferroni test have been used for statistical analysis, with P , 0.05 taken as statistically significant. In vivo two-photon Ca 21 imaging. All experimental procedures were in compliance with institutional animal welfare guidelines and were approved by the state government of Bavaria, Germany. The animal preparation procedure was similar to that described previously 25 . In brief, C57Bl/6 mice (male or female, ,P40) were anaesthetized with isoflurane (1-1.5%) and placed onto a warming plate (37-38 uC). The skin was removed and a custom-made recording chamber was glued to the exposed skull. A craniotomy (,1 mm) was made over the LETTER RESEARCH hippocampus (2.5 mm posterior to bregma, 2.2 mm lateral to the midline) and a small portion of the overlying cortical tissue was carefully removed by aspiration. The animal was placed under a microscope on a warm heating plate (37-38 uC) and kept anaesthetized with low-levels of isoflurane (,0.8%). Respiratory and pulse rates were continuously monitored. The recording chamber was perfused with warm normal Ringer's solution containing 125 mM NaCl, 4.5 mM KCl, 26 mM NaHCO 3 , 1.25 mM NaH 2 PO 4 , 2 mM CaCl 2 , 1 mM MgCl 2 and 20 mM glucose (pH 7.4 when bubbled with 95% O 2 and 5% CO 2 ). The exposed CA1 region of the hippocampus was then stained with fluo-8AM (AAT Bioquest; 0.6 mM) using the multi-cell bolus loading technique 54 .
In vivo imaging was performed with a custom-built two-photon microscope equipped with a Ti:sapphire laser system (Coherent; laser wavelength 925 nm), a resonant scanner and a Pockel's cell for laser intensity modulation. Full-frame images were acquired at 30 Hz using a water-immersion objective (Nikon; 403, 0.8 numerical aperture). Data acquisition was controlled using custom-written software based on LabVIEW (National Instruments). Image analysis was performed off-line by using custom routines in LabVIEW and Igor Pro (Wavemetrics). Cellular regions of interest were drawn around individual somata, and then relative fluorescence change (DF/F) versus time traces were generated for each region of interest. Ca 21 transients were identified as changes in DF/F that were three times larger than the s.d. of the noise band.
To assess the effects of Ag peptides on neuronal activity in vivo, the peptides or the respective controls (SEC fractions obtained from untransfected CHO cells or a synthetic peptide (46 amino acids; 1-ADSVPANTENEVEPVDARPAADRGL TTRPGSGLTNIKTEEISEVKM-46) of a middle part of Ag were added to the normal Ringer's solution used for perfusion of the recording chamber (bathapplication technique; 45-60 min each wash-in). In a subset of experiments, synthetic Ag-a (92 amino acids; 1-MISEPRISYGNDALMPSLTETKTTVELLPV NGEFSLDDLQPWHSFGADSVPANTENEVEPVDARPAADRGLTTRPGSGLT NIKTEEISEVKM-92) was applied locally by gentle pressure injection through a glass pipette that was placed close to the neurons of interest (local application technique; 40 s each pressure injection).
The samples were blinded to the investigator and uncoded at the end of the experiments. Statistical analysis was performed using SPSS. The statistical methods used were the Student's t-test and the Fisher's exact test. P , 0.05 was considered statistically significant. RESEARCH LETTER
